Episode Details
Join us this week as we welcome Ann Mond Johnson, CEO of the American Telemedicine Association
- Anne Mond Johnson is the CEO of the American Telemedicine Association (ATA), which aims to make telehealth a regular modality of healthcare.
- The ATA has been pivotal in advocating for federal waivers to extend telehealth services during the COVID-19 pandemic.
- Before the pandemic, various regulations and limitations restricted telehealth adoption.
- The ATA focuses on turning temporary waivers into permanent changes.
- Telehealth can play a role in addressing healthcare disparities by reaching underserved communities.
- Building trust with local communities is crucial for the successful adoption of telehealth services.
Watch
Listen
Read
Introduction
In the ever-evolving landscape of healthcare, Digital Therapeutics (DTX) is emerging as a groundbreaking approach with immense potential. Cognitive health, in particular, is an area poised for significant advancements through the application of digital tools. Our conversation with Jordan Glenn, Chief Science Officer at Neurotrack, sheds light on how digital therapeutics can revolutionize the assessment and management of cognitive impairments.
Jordan Glenn: A Personalized Journey Into Cognitive Health
The pivot in Jordan Glenn’s career towards cognitive health was far from accidental. Moved by his future father-in-law’s battle with Alzheimer’s, Glenn transitioned from researching modifiable risk factors for conditions like diabetes to focusing on cognitive diseases.
The Importance of Digital Assessment in Cognitive Health
Glenn firmly believes that accurate measurement is at the core of effective treatment. Traditional assessments for cognitive impairment are often skipped in medical settings due to time constraints, creating a significant gap in healthcare. Neurotrack aims to address this by providing rapid and precise digital assessments that can be easily incorporated into medical visits.
Real-world Challenges in Implementing Digital Therapeutics
Implementation is rarely straightforward when it comes to integrating new technologies into healthcare systems. “There’s how healthcare is supposed to work, and then there’s how healthcare actually works,” Glenn notes. This realization led Neurotrack to develop a flexible product that can adapt to the unique workflow challenges of diverse healthcare settings.
The Urgency of Early Detection
Early identification of cognitive impairment is vital, especially for diseases like Alzheimer’s where options for reversal are limited. Glenn concurs that the emphasis should be on early detection to facilitate timely interventions that can slow the progression of the disease. Digital assessments, like those offered by Neurotrack, play a crucial role in this early diagnosis and subsequent management of cognitive conditions.
Conclusion
The work by Neurotrack and its Chief Science Officer, Jordan Glenn, epitomizes the innovation driving the digital therapeutics industry, especially in the field of cognitive health. Their focus on creating efficient, easily-administered digital assessments is filling a vital gap in healthcare, offering a glimpse of hope in the challenging landscape of cognitive impairments. Their contributions underline the importance of a flexible and adaptive approach in implementing digital therapeutics effectively within healthcare systems, paving the way for better management of cognitive diseases.
To learn more about Jordan Glenn and Neurotrack please use the links below:
– Jordan’s LinkedIn – Nuerotrack’s LinkedIn – Nuerotrack’s Website
Also, be sure to follow DTx Equals on our social channels:
